Testing emicizumab for type 3 von Willebrand disease
Treatments studied
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests whether emicizumab can help prevent or treat bleeding episodes in people with type 3 von Willebrand disease, a rare and severe bleeding disorder. It may offer a new option for those who have not had good control with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of type 3 von Willebrand disease (a severe form of a bleeding disorder).
- You must have had at least 2 bleeding episodes (not including menstrual bleeding) treated with clotting factor concentrates in the 6 months before joining.
- You need to have had previous treatment with standard therapy (either on-demand or as a preventive shot 1-3 times weekly).
- You must have adequate blood cell counts, liver and kidney function.
- You cannot have other bleeding disorders (other than type 3 VWD), recent stomach bleeding, or a history of bleeding in the brain.
- You must agree to use effective contraception if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies how well and safely emicizumab works for people with severe von Willebrand disease (VWD) or VWD plus hemophilia A. Emicizumab is a preventive medicine given regularly to reduce bleeding risk.
This study is testing a new treatment for people with certain types of Von Willebrand disease (Type 1 or 2A) who have frequent bleeding problems. It aims to see if the treatment can help reduce these bleeding episodes.
This trial tests a new drug called VGA039 that is injected under the skin to prevent bleeding episodes in people with von Willebrand disease. It is for those who bleed frequently and are not currently using regular preventive treatments.
This Phase 1/2 study tests VGA039 in healthy adults and people with von Willebrand disease (VWD). The goal is to see if the drug is safe and how it affects bleeding-related factors, especially in people who have symptoms.
This Phase 3 trial tests vonicog alfa (an rVWF treatment) to prevent and control bleeding in children with severe von Willebrand disease (vWD). You may be able to join if your child has severe vWD and has been on prior clotting factor treatment with ongoing bleeding despite that care.
This Phase 3 trial tests an recombinant version of the von Willebrand factor (rVWF) for people with severe von Willebrand disease (VWD) living in China. It aims to see if the drug can safely control bleeding and help those who need regular clotting factor treatments.
Hear when a new Von Willebrand Disease, Type 3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.